Equillium GAAP EPS of -$0.06 beats by $0.01
Source: SeekingAlpha
2025-11-13 16:59:08 ET
More on Equillium
- Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases - Slideshow
- Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript
- Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC
- Seeking Alpha’s Quant Rating on Equillium
- Historical earnings data for Equillium
Read the full article on Seeking Alpha
For further details see:
Equillium GAAP EPS of -$0.06 beats by $0.01
Equillium Inc.
NASDAQ: EQ
EQ Trading
10.12% G/L:
$1.9491 Last:
116,517 Volume:
$2.01 Open:
EQ Latest News
February 25, 2026 08:30:00 am
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
November 13, 2025 04:05:00 pm
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
EQ Stock Data
$92,862,257
41,651,006
0.15%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
La Jolla
